PA

Your Article Summary

See Latest Articles

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children
Clinical Therapeutics, 10/29/09

Abelson MB et al. – In this CAC model of allergic conjunctivitis in adults and children, bepotastine besilate ophthalmic solutions 1.0% and 1.5% were associated with clinically and statistically significant reductions in ocular itching, but not conjunctival hyperemia, within 15 minutes that were maintained for at least 8 hours after administration. Both solutions were well tolerated.

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09

Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09

See All of Clinical Pharmacology

Today in Ophthalmology...keeping you current

Receive free subspecialty "5-minute updates" via email

Evidence-based treatment of acute infective conjunctivitis: Breaking the cycle of antibiotic prescribing
Canadian Family Physician, 11/13/09

Primary extranodal marginal zone lymphoma of the uvea associated with massive diffuse epibulbar extension and focal infiltration of the optic nerve and meninges, clinically presented as uveitis masquerade syndrome: a case report
Medical Oncology, 10/16/09

Intravascular presence of tumor cells as prognostic parameter in uveal melanoma: a 35-year survey
Investigative Ophthalmology and Visual Science, 10/15/09

See All of Ophthalmology